Reported about 11 hours ago
Kimberly-Clark has announced its acquisition of Kenvue, the maker of Tylenol, in a deal valued at $48.7 billion, with the transaction expected to finalize in the second half of next year. Following the announcement, Kenvue's shares surged by over 17%, while Kimberly-Clark's shares fell nearly 13%. This strategic move reflects Kimberly-Clark's efforts to enhance its portfolio amidst challenges within the consumer packaged goods sector, as both companies have seen significant stock declines in 2025.
Source: YAHOO